Phase II Study of Pembrolizumab (MK-3475) as First-Line Therapy for High Risk T1 Non-Muscle-Invasive Bladder Cancer
Phase of Trial: Phase II
Latest Information Update: 06 Jul 2018
Price : $35 *
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Bladder cancer
- Focus Therapeutic Use
- 27 Jun 2018 Planned End Date changed from 1 Apr 2019 to 1 Apr 2020.
- 27 Jun 2018 Planned primary completion date changed from 1 Apr 2019 to 1 Apr 2020.
- 27 Jun 2018 Status changed from not yet recruiting to recruiting.